Correlation Between Aerovate Therapeutics and ArriVent BioPharma,
Can any of the company-specific risk be diversified away by investing in both Aerovate Therapeutics and ArriVent BioPharma, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aerovate Therapeutics and ArriVent BioPharma, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aerovate Therapeutics and ArriVent BioPharma, Common, you can compare the effects of market volatilities on Aerovate Therapeutics and ArriVent BioPharma, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aerovate Therapeutics with a short position of ArriVent BioPharma,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aerovate Therapeutics and ArriVent BioPharma,.
Diversification Opportunities for Aerovate Therapeutics and ArriVent BioPharma,
0.45 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Aerovate and ArriVent is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding Aerovate Therapeutics and ArriVent BioPharma, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ArriVent BioPharma, and Aerovate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aerovate Therapeutics are associated (or correlated) with ArriVent BioPharma,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ArriVent BioPharma, has no effect on the direction of Aerovate Therapeutics i.e., Aerovate Therapeutics and ArriVent BioPharma, go up and down completely randomly.
Pair Corralation between Aerovate Therapeutics and ArriVent BioPharma,
Given the investment horizon of 90 days Aerovate Therapeutics is expected to generate 0.72 times more return on investment than ArriVent BioPharma,. However, Aerovate Therapeutics is 1.39 times less risky than ArriVent BioPharma,. It trades about -0.13 of its potential returns per unit of risk. ArriVent BioPharma, Common is currently generating about -0.22 per unit of risk. If you would invest 257.00 in Aerovate Therapeutics on November 28, 2024 and sell it today you would lose (16.00) from holding Aerovate Therapeutics or give up 6.23% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Aerovate Therapeutics vs. ArriVent BioPharma, Common
Performance |
| Timeline |
| Aerovate Therapeutics |
| ArriVent BioPharma, |
Aerovate Therapeutics and ArriVent BioPharma, Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Aerovate Therapeutics and ArriVent BioPharma,
The main advantage of trading using opposite Aerovate Therapeutics and ArriVent BioPharma, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aerovate Therapeutics position performs unexpectedly, ArriVent BioPharma, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma, will offset losses from the drop in ArriVent BioPharma,'s long position.| Aerovate Therapeutics vs. Adagene | Aerovate Therapeutics vs. Acrivon Therapeutics, Common | Aerovate Therapeutics vs. Rezolute | Aerovate Therapeutics vs. AN2 Therapeutics |
| ArriVent BioPharma, vs. Yuexiu Transport Infrastructure | ArriVent BioPharma, vs. Rambler Metals and | ArriVent BioPharma, vs. Pearson PLC ADR | ArriVent BioPharma, vs. Afya |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Complementary Tools
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |